RNS Number : 6980U MaxCyte, Inc. 02 July 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights ROCKVILLE, MD , July 2, 2024 : MaxCyte Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the
RNS Number : 2055U MaxCyte, Inc. 27 June 2024 Publication of Annual Report ROCKVILLE, MD , June 27, 2024 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and
RNS Number : 4058S MaxCyte, Inc. 14 June 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Grant of Options and Restricted Stock Units ROCKVILLE, MD , June 14, 2024 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 0511S MaxCyte, Inc. 12 June 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Results of AGM Rockville, Maryland - June 12 , 2024: MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the
RNS Number : 9400R MaxCyte, Inc. 11 June 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") PDMR Dealing ROCKVILLE, MD , June 12, 2024 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery,
RNS Number : 9173Q MaxCyte, Inc. 03 June 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights and Block Listing Return ROCKVILLE, MD , June 3, 2024 : MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
ROCKVILLE, Md., May 29, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative
RNS Number : 2809Q MaxCyte, Inc. 29 May 2024 MaxCyte to Participate in William Blair 44 th Annual Growth Stock Conference Rockville, MD , May 29, 2024 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the
Legend Biotech obtains license to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its non-viral engineered pipeline portfolio across a variety of cell types including T cells, Gamma-Delta T cells and NK Cells. ROCKVILLE, Md., May 22, 2024 (GLOBE NEWSWIRE) -- MaxCyte,
RNS Number : 4603P MaxCyte, Inc. 22 May 2024 4867-2449-5548v.1 MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development Legend Biotech obtains license to use MaxCyte's Flow Electroporation® technology and
